ClinicalTrials.gg
RecruitingNCT02710786Updated Dec 26, 2023

Comorbidity After Gastric Bypass

An observational study in Severe Obesity, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Uppsala University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started May 2007; still recruiting 19 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Obesity, Morbid with a site in Sweden — 3 open to participants now, 5 under way, none of them phase 3. Obesity, Morbid · Sweden.

Started
2007
the only one that year
Observational
7 of 16
3 open now
Registered
11th of 16
by date
Lead sponsor
2 of 16
Uppsala University

Among the 16 studies in Obesity, Morbid with a site in Sweden, this one is the only one that started in 2007, is one of 7 observational ones, and was the 11th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

3 of the 16 studies in Obesity, Morbid with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Obesity, Morbid with a site in Sweden, or all of them as a file.
02

Study summary

To evaluate effect on comorbid disease and weight loss in the long-term (>five years) after Roux-en-Y gastric bypass (RYGB) surgery for severe obesity.

Read the detailed description

Individuals with severe obesity frequently have comorbid diseases, e.g. diabetes, hypertension, hyperlipidemia, and sleep apnea. We will study the remission rate and weight loss in the long-term (10 years) after Roux-en-Y gastric bypass (RYGB) surgery in a nationwide large group of patients.

03

Conditions studied

  • Severe Obesity

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Individuals undergoing gastric bypass

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Registered individuals in Scandinavian Obesity Surgery Registry (SOReg) having had gastric bypass

Exclusion criteria

Exclusion Criteria:

  • All other operations
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
15 Years
Patient registry
Yes

Groups and cohorts

  • Gastric bypass

    Patients undergoing gastric bypass

    Procedure: Gastric bypass

Interventions

  • ProcedureGastric bypass

    Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach

06

What researchers measure

Primary outcomes

  1. Change in comorbid conditions, as defined by use of pharmacological treatment

    Remission of diabetes mellitus, hypertension, dyslipidemia, and depression as defined by use of pharmacological treatment, and sleep apnea as defined by use of CPAP. Data will be collected from SOReg.

    Time frame: 10 years

Secondary outcomes

  1. Number of patients with pathological laboratory data (corresponding to the studied comorbid conditions)

    Glucose, HbA1c, LDL, HDL, triglycerides, and blood pressure

    Time frame: 10 years

  2. Weight loss

    Peroperative weight (in kg) minus current weight (in kg)

    Time frame: 10 years

  3. BMI loss

    Peroperative BMI minus current BMI. Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2007 (actual). Primary completion is estimated for Jan 2025, 212 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 212 months is above that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 17, 2016
StartActual
May 2007
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02710786
Lead sponsor
Uppsala University
Collaborators
Karolinska Institutet, The Scandinavian Obesity Surgery Registry
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
May 2007
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Dec 26, 2023

Study contacts

Erik Näslund
Contact
erik.naslund@ki.se
Magnus Sundbom
Contact
magnus.sundbom@surgsci.uu.se
Ingemar Näslund
study chair · Scandinavian Obesity Surgery Registry

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion